What is the fair value of Novartis AG (OTC-NVSE.F) stock?

The current fair value estimate for Novartis AG (OTC-NVSE.F) is $157.32. This implies an estimated upside of 13.7% versus the current market price.

Is Novartis AG (OTC-NVSE.F) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 13.7% versus the current market price.

How is the financial health of Novartis AG?

The current financial health read for Novartis AG (OTC-NVSE.F) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Novartis AG's next earnings date?

The next earnings date currently listed for Novartis AG (OTC-NVSE.F) is October 27, 2026.

Does Novartis AG (OTC-NVSE.F) pay dividends?

Based on the current data, dividend yield is 3.4%.

What is the P/E ratio for Novartis AG (OTC-NVSE.F)?

The current P/E ratio listed for Novartis AG (OTC-NVSE.F) is 21.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Novartis AG?

The current market capitalization listed for Novartis AG is 269.8 B.

What is the enterprise value of Novartis AG?

The current enterprise value listed for Novartis AG is 310.4 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Novartis AG?

The ticker symbol for Novartis AG is OTC-NVSE.F, and the stock is listed on OTC Markets.

Where is Novartis AG (OTC-NVSE.F) listed?

Novartis AG (OTC-NVSE.F) is listed on OTC Markets.

What is the debt-to-total-capital ratio for Novartis AG?

The current debt-to-total-capital ratio listed for Novartis AG is 15.4%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Novartis AG?

The free float listed for Novartis AG is 97.7%. Free float helps investors understand how much of the share base is available for public trading.

Novartis AG (NVSEF) Fair Value & Stock Analysis

Novartis AG (NVSEF)

Novartis AG is a Swiss pharmaceutical company listed on OTC Markets as common stock. The company is engaged in the research, development, manufacture, distribution, marketing, and sale of medicines in Switzerland and internationally. Its portfolio includes therapies across several therapeutic areas, including cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. Products mentioned in the source include Entresto for chronic heart failure with reduced ejection fraction, Cosentyx for several inflammatory conditions, Kisqali, Promacta/Revolade, Tafinlar+Mekinist, Jakavi, Tasigna, Xolair, Ilaris, Pluvicto, Sandostatin SC and Sandostatin LAR, Zolgensma, Lucentis, Leqvio, Lutathera, Scemblix, and Fabhalta. Novartis also has a license and collaboration agreement with Alnylam Pharmaceuticals related to Leqvio. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
OTC-NVSE.F	$157.32	13.7% Upside	Fair	Not available	Not available	Great	3.4%	October 27, 2026	21.1x	6.5x	4.8x	269.8 B	310.4 B	15.4%	97.7%	8.0	71.1%	131.4%